RARE today
$16.70+$0.56 (+3.47%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minLeaning Bullish
Daily trend turns down below $15.85
Key levels
Resistance$19.61
Resistance$17.67
Support$16.31
Support$15.12
Latest news & SEC filings
AnalystLeerink Partners keeps Buy rating and $33 target on Ultragenyx Pharmaceutical
ProductUltragenyx reports UK regulator accepted its filing for Rebisufligene Etisparvovec
AnalystCitigroup keeps Buy rating on Ultragenyx Pharmaceutical, cuts target to $22
All RARE news →About Ultragenyx
Ultragenyx Pharmaceutical is a biopharmaceutical company that develops and commercializes treatments for rare and ultra-rare genetic diseases. Its portfolio includes approved therapies and product candidates in gene therapy, biologics, and small molecules, with a focus on areas such as bone, muscle, and metabolic disorders. The company operates in the United States and internationally, serving patients through partnerships with other pharmaceutical firms and healthcare providers.
Based on the company's 10-K filed Feb 18, 2026.
Nasdaq · Healthcare
Ultragenyx Pharmaceutical Inc. (RARE)
What Is the Price Target for RARE?
SEPT Low Target
$16.00
SEPT Mid Target
$22.00
SEPT High Target
$39.00
Analyst Consensus
$22.00
Is RARE a Buy or Sell Right Now?
Thesis
- •Revenue growing 20.2% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RARE.
Start Free Trial →Is RARE Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$22.00
16
Moat Score
NONE
4/9
Piotroski Score
-3.8
Altman Z-Score
What Is Smart Money Doing with RARE?
Insider Signal
SELLING
0 buys / 6 sells (90d)
Congress Signal
BUYING
2 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D. | director | Sale | 2,000 | $50K | Jun 15, 2026 |
| Parschauer Karah Herdman | officer | Sale | 1,899 | $47K | Jun 15, 2026 |
| Horn Howard | officer | Sale | 4,653 | $111K | Jun 1, 2026 |
| SULIMAN SHEHNAAZ | director | Sale | 5,740 | $144K | May 18, 2026 |
| Ray Amrit | director | Buy | 7,751 | - | May 14, 2026 |
| Sanders Corazon (Corsee) D. | director | Buy | 7,751 | - | May 14, 2026 |
| SULIMAN SHEHNAAZ | director | Buy | 7,751 | - | May 14, 2026 |
| Fust Matthew K | director | Buy | 7,751 | - | May 14, 2026 |
| NARACHI MICHAEL | director | Buy | 7,751 | - | May 14, 2026 |
| WELCH DANIEL G | director | Buy | 7,751 | - | May 14, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RARE Growth Story
Revenue YoY
20.2%
3yr Revenue CAGR
22.8%
EPS Growth YoY
7.31%
FCF Growth YoY
-12.1%
Revenue Trend
STRONG
Dark Pool Trades for RARE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RARE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:02:16 | $16.65 | 5,000 | $$83K | BUY |
| 21:00:12 | $16.70 | 14,127 | $$236K | BUY |
| 21:00:00 | $16.70 | 2,800 | $$47K | BUY |
| 21:00:00 | $16.70 | 1,346 | $$22K | BUY |
| 21:00:00 | $16.70 | 1,232 | $$21K | BUY |
5 dark pool trades shown · $$409K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for RARE
PREVIEWSEPT Investing provides real-time options flow tracking for RARE, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $25 | Feb 19 | 100 | $$55 | 1 | SWEEP |
| CALL | $25 | Feb 19 | 100 | $$275 | 5 | SWEEP |
| CALL | $25 | Feb 19 | 100 | $$275 | 5 | SWEEP |
| CALL | $25 | Feb 19 | 100 | $$275 | 5 | SWEEP |
| CALL | $25 | Feb 19 | 100 | $$275 | 5 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Ultragenyx Pharmaceutical Inc. (RARE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RARE — frequently asked questions
What is RARE stock price today?
Ultragenyx Pharmaceutical Inc. (RARE) is at $16.70, up 3.47% (+$0.56) at the Nov 11, 2026 close.
Why is RARE stock moving today?
Latest RARE news — Nov 6, 2026: Leerink Partners keeps Buy rating and $33 target on Ultragenyx Pharmaceutical · Nov 6, 2026: Ultragenyx reports UK regulator accepted its filing for Rebisufligene Etisparvovec
What is the RARE price target?
The average analyst price target for RARE is $22.00, ranging from $16 to $39, based on 16 analysts. Latest: Leerink Partners maintains on Nov 6, 2026.
What do analysts rate RARE?
Analyst ratings for RARE: 0 Buy, 40 Hold, 3 Sell — consensus Hold.
Did RARE beat earnings?
RARE last reported on Nov 3, 2026: EPS -$1.16 vs -$1.10 expected — a miss of 5.5%.
Does RARE pay a dividend?
RARE does not currently pay a dividend.
What are RARE support and resistance levels?
Support: $16.31, $15.12, $14.08. Resistance: $17.67, $19.61, $21.39.
What are insiders doing with RARE?
Insider activity: SELLING, 0 buys and 6 sells in the last 90 days.
What is the latest news on RARE?
Nov 6, 2026: Leerink Partners keeps Buy rating and $33 target on Ultragenyx Pharmaceutical · Nov 6, 2026: Ultragenyx reports UK regulator accepted its filing for Rebisufligene Etisparvovec · Nov 5, 2026: Citigroup keeps Buy rating on Ultragenyx Pharmaceutical, cuts target to $22